Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00

Denali Therapeutics (NASDAQ:DNLI) had its price target boosted by Morgan Stanley from $40.00 to $42.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research analysts have also commented on the stock. Robert W. Baird upped their price objective on shares of Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Thursday. UBS Group began coverage on Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating on the stock. Jefferies Financial Group restated a “buy” rating and set a $40.00 price target on shares of Denali Therapeutics in a research note on Monday, March 2nd. Wolfe Research started coverage on Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, The Goldman Sachs Group raised their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.82.

Denali Therapeutics Trading Down 8.0%

Shares of DNLI stock opened at $18.16 on Thursday. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77. The firm’s fifty day simple moving average is $20.43 and its 200 day simple moving average is $17.85. The firm has a market capitalization of $2.88 billion, a P/E ratio of -6.11 and a beta of 1.02. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same quarter last year, the firm earned ($0.67) EPS. As a group, sell-side analysts predict that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Transactions at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in Denali Therapeutics in the 3rd quarter valued at $29,000. State of Wyoming acquired a new stake in Denali Therapeutics in the 2nd quarter valued at $29,000. Aster Capital Management DIFC Ltd bought a new stake in Denali Therapeutics in the fourth quarter valued at $57,000. Finally, Quarry LP bought a new stake in Denali Therapeutics in the third quarter valued at $64,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics News Roundup

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.